[go: up one dir, main page]

NI201700060A - Agonistas parciales del receptor de insulina - Google Patents

Agonistas parciales del receptor de insulina

Info

Publication number
NI201700060A
NI201700060A NI201700060A NI201700060A NI201700060A NI 201700060 A NI201700060 A NI 201700060A NI 201700060 A NI201700060 A NI 201700060A NI 201700060 A NI201700060 A NI 201700060A NI 201700060 A NI201700060 A NI 201700060A
Authority
NI
Nicaragua
Prior art keywords
insulin receptor
receptor agonists
partial insulin
partial
insulin
Prior art date
Application number
NI201700060A
Other languages
English (en)
Inventor
Lin Songnian
Yan Lin
Huo Pei
Pissarnitski Dmitri
Feng Danqing
Nargund Ravi
Zhu Yuping
Kekec Ahmet
Christina Madsen-Duggan B
Shi Zhi-Cai
Wu Zhicai
Mu Yingjun
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of NI201700060A publication Critical patent/NI201700060A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/62Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se divulgan dimeros de insulina y dimeros de análogo de insulina que actúan como agonistas parciales en el receptor de insulina.
NI201700060A 2014-11-21 2017-05-19 Agonistas parciales del receptor de insulina NI201700060A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462082857P 2014-11-21 2014-11-21
US201562242503P 2015-10-16 2015-10-16

Publications (1)

Publication Number Publication Date
NI201700060A true NI201700060A (es) 2017-07-18

Family

ID=54838417

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201700060A NI201700060A (es) 2014-11-21 2017-05-19 Agonistas parciales del receptor de insulina

Country Status (26)

Country Link
US (4) US20170355743A1 (es)
EP (4) EP3666792B1 (es)
JP (5) JP6484337B2 (es)
KR (2) KR102049647B1 (es)
CN (2) CN112494656B (es)
AR (1) AR102712A1 (es)
AU (3) AU2015349890B2 (es)
CA (2) CA2966765C (es)
CL (3) CL2017001288A1 (es)
CO (1) CO2017004976A2 (es)
CR (1) CR20170208A (es)
DO (1) DOP2017000124A (es)
EA (1) EA036714B1 (es)
ES (2) ES3004386T3 (es)
GT (1) GT201700104A (es)
IL (1) IL252257A0 (es)
MX (3) MX2017006651A (es)
NI (1) NI201700060A (es)
PE (1) PE20170957A1 (es)
PH (1) PH12017500935A1 (es)
SG (4) SG10201809428UA (es)
SV (1) SV2017005445A (es)
TN (1) TN2017000178A1 (es)
TW (1) TW201625673A (es)
WO (1) WO2016081670A2 (es)
ZA (1) ZA201703238B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3177612T3 (da) 2014-08-04 2022-05-16 Nuevolution As Eventuelt fusionerede heterocyclylsubstituerede derivater af pyrimidin, der er anvendelige til behandling af inflammatoriske, metaboliske, onkologiske og autoimmune sygdomme
KR102049647B1 (ko) * 2014-11-21 2019-11-29 머크 샤프 앤드 돔 코포레이션 인슐린 수용체 부분 효능제
AR105616A1 (es) 2015-05-07 2017-10-25 Lilly Co Eli Proteínas de fusión
US10953076B2 (en) 2016-05-24 2021-03-23 Merck Sharp & Dohme Corp. Insulin receptor partial agonists and GLP-1 analogues
EP3463413A4 (en) * 2016-05-25 2020-03-04 Merck Sharp & Dohme Corp. Insulin receptor partial agonists
JP7022746B2 (ja) * 2016-10-24 2022-02-18 ノヴォ ノルディスク アー/エス インスリン製剤のためのバイオアッセイ
EP3668892A1 (en) 2017-08-17 2020-06-24 Novo Nordisk A/S Novel acylated insulin analogues and uses thereof
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US12097263B2 (en) 2018-08-02 2024-09-24 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
WO2020028864A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
CA3108282A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11911484B2 (en) 2018-08-02 2024-02-27 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
CN112898172B (zh) * 2019-12-04 2022-05-31 中国科学院大连化学物理研究所 可被羧肽酶酶解的双亲和功能团化合物的合成方法
JP2021098692A (ja) 2019-12-20 2021-07-01 ヌエヴォリューション・アクティーゼルスカブNuevolution A/S 核内受容体に対して活性の化合物
WO2021198956A1 (en) 2020-03-31 2021-10-07 Nuevolution A/S Compounds active towards nuclear receptors
JP2023519603A (ja) 2020-03-31 2023-05-11 ヌエヴォリューション・アクティーゼルスカブ 核内受容体に対して活性な化合物
US20230310551A1 (en) * 2020-08-26 2023-10-05 Merck Sharp & Dohme Llc Insulin receptor partial agonists
US20250051416A1 (en) * 2020-08-26 2025-02-13 Merck Sharp & Dohme Llc Insulin receptor partial agonists
EP4208173A1 (en) * 2020-09-03 2023-07-12 Dyne Therapeutics, Inc. Methods of preparing protein-oligonucleotide complexes
CN116457015A (zh) * 2020-09-03 2023-07-18 达因疗法公司 制备蛋白质-寡核苷酸复合物的方法
WO2022055877A2 (en) * 2020-09-09 2022-03-17 Merck Sharp & Dohme Corp. Insulin receptor partial agonists
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11648318B2 (en) 2021-07-09 2023-05-16 Dyne Therapeutics, Inc. Anti-transferrin receptor (TFR) antibody and uses thereof
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
KR20240035825A (ko) 2021-07-09 2024-03-18 다인 세라퓨틱스, 인크. 디스트로핀병증을 치료하기 위한 근육 표적화 복합체 및 제제
US11633498B2 (en) 2021-07-09 2023-04-25 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
CN119183457A (zh) 2022-04-15 2024-12-24 达因疗法公司 用于治疗强直性肌营养不良的肌肉靶向复合物和制剂

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1381273A (en) * 1971-01-28 1975-01-22 Nat Res Dev Insulin derivatives
US3907763A (en) 1972-03-01 1975-09-23 Bayer Ag Insulin derivatives crosslinked by a dicarboxylic acid moiety
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
US5514646A (en) 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
US5304473A (en) 1991-06-11 1994-04-19 Eli Lilly And Company A-C-B proinsulin, method of manufacturing and using same, and intermediates in insulin production
AU1272295A (en) 1993-12-17 1995-07-03 Novo Nordisk A/S Proinsulin-like compounds
AU5724996A (en) 1995-05-05 1996-11-21 Eli Lilly And Company Single chain insulin with high bioactivity
WO1999063932A2 (en) * 1998-06-08 1999-12-16 Advanced Medicine, Inc. Multibinding agents that modulate the 5-ht transporter
DE19908041A1 (de) * 1999-02-24 2000-08-31 Hoecker Hartwig Kovalent verbrückte Insulindimere
KR100449454B1 (ko) 2000-10-02 2004-09-21 이현철 단일사슬 인슐린 유도체의 유전자를 포함하는 당뇨병치료용 벡터
WO2002067969A2 (en) 2001-02-21 2002-09-06 Medtronic Minimed, Inc. Stabilized insulin formulations
US7105314B2 (en) 2001-04-02 2006-09-12 Novo Nordisk A/S Method for making human insulin precursors
EP2226316B1 (en) 2002-05-30 2016-01-13 The Scripps Research Institute Copper-catalysed ligation of azides and acetylenes
KR100507796B1 (ko) 2003-04-03 2005-08-17 한미약품 주식회사 생체내 반감기가 증가된 peg-생리활성 폴리펩티드 동종이량체 결합체 및 이의 제조방법
AU2004295023A1 (en) 2003-12-03 2005-06-16 Novo Nordisk A/S Single-chain insulin
US20090197800A1 (en) 2004-10-27 2009-08-06 Novo Nordisk A/S Insulin Receptor Binding Peptides with Non-Insulin Gene Activation Profiles and Uses Thereof
WO2006050262A2 (en) 2004-11-01 2006-05-11 The Regents Of The University Of California Compositions and methods for modification of biomolecules
JP2008533100A (ja) 2005-03-18 2008-08-21 ノボ ノルディスク アクティーゼルスカブ Peg化された単鎖インスリン
EP1991575A1 (en) 2006-02-21 2008-11-19 Novo Nordisk A/S Single-chain insulin analogues and pharmaceutical formulations thereof
US20090069215A1 (en) 2006-03-13 2009-03-12 Novo Nordisk A/S Acylated Single Chain Insulin
JP2009530243A (ja) 2006-03-13 2009-08-27 ノボ・ノルデイスク・エー/エス アシル化単鎖インスリン
WO2007104736A2 (en) 2006-03-13 2007-09-20 Novo Nordisk A/S Acylated single chain insulin
WO2007104734A1 (en) 2006-03-13 2007-09-20 Novo Nordisk A/S Acylated single chain insulin
JP5256199B2 (ja) 2006-08-07 2013-08-07 テヴァ バイオファーマシューティカルズ ユーエスエー,インコーポレーティッド アルブミン−インスリン融合タンパク質
WO2008145721A2 (en) * 2007-06-01 2008-12-04 Novo Nordisk A/S N-terminal modification of polypeptides for protection against degradation by aminopeptidases
EP2249853A4 (en) 2008-01-30 2012-12-26 Univ Indiana Res & Tech Corp ESTER BASED PEPTIDE PRODRUGS
CA2722168A1 (en) 2008-04-22 2009-10-29 Case Western Reserve University Isoform-specific insulin analogues
TWI394580B (zh) * 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
EP3228320B1 (de) * 2008-10-17 2019-12-18 Sanofi-Aventis Deutschland GmbH Kombination von einem insulin und einem glp-1-agonisten
CN102245624B (zh) 2008-12-19 2016-08-10 印第安纳大学研究及科技有限公司 基于酰胺的胰岛素前药
AU2009335712B2 (en) 2008-12-19 2015-09-17 Indiana University Research And Technology Corporation Insulin analogs
WO2011059895A1 (en) 2009-11-11 2011-05-19 Quest Diagnostics Investments Incorporated Hexa mutations
AU2011268327B2 (en) * 2010-06-16 2016-02-25 Indiana University Research And Technology Corporation Single chain insulin agonists exhibiting high activity at the insulin receptor
US8255297B2 (en) 2010-07-20 2012-08-28 Facebook, Inc. Creation, redemption, and accounting in a virtual currency system
WO2012049307A2 (en) 2010-10-15 2012-04-19 Novo Nordisk A/S Novel n-terminally modified insulin derivatives
CN104010652A (zh) * 2011-10-27 2014-08-27 卡斯西部储备大学 超浓缩的速效胰岛素类似物制剂
WO2014052451A2 (en) * 2012-09-26 2014-04-03 Indiana University Research And Technology Corporation Insulin analog dimers
US20160067212A1 (en) 2013-03-15 2016-03-10 Universite De Geneve Use of insulin signaling antagonists, optionally in combination of transfection of non-beta cells, for inducing insulin production
CN105792852B (zh) * 2013-10-04 2019-12-10 默沙东公司 葡萄糖响应性的胰岛素缀合物
US10758636B2 (en) * 2013-11-12 2020-09-01 Centre For Probe Development And Commercialization Residualizing linkers and uses thereof
MX369656B (es) 2014-01-20 2019-11-15 Hanmi Pharm Ind Co Ltd Insulina de accion prolongada y uso de la misma.
KR102049647B1 (ko) 2014-11-21 2019-11-29 머크 샤프 앤드 돔 코포레이션 인슐린 수용체 부분 효능제

Also Published As

Publication number Publication date
JP2020097572A (ja) 2020-06-25
JP2019014735A (ja) 2019-01-31
CA2966765C (en) 2020-04-14
US10183981B2 (en) 2019-01-22
AU2018211208A1 (en) 2018-08-16
PH12017500935A1 (en) 2017-11-27
EP3660041B1 (en) 2023-04-19
ES3004386T3 (en) 2025-03-12
BR112017010481A2 (pt) 2018-04-03
AU2015349890A1 (en) 2017-06-01
CL2019001143A1 (es) 2019-07-19
AU2018211207A1 (en) 2018-08-16
AU2018211208B2 (en) 2020-09-10
CA3014641C (en) 2020-08-18
WO2016081670A3 (en) 2016-08-04
EA201791117A1 (ru) 2017-11-30
CN112494656B (zh) 2024-01-30
MX2020014121A (es) 2021-03-25
US20180291078A1 (en) 2018-10-11
EP3221343A2 (en) 2017-09-27
JP6931033B2 (ja) 2021-09-01
WO2016081670A2 (en) 2016-05-26
EP3660041A1 (en) 2020-06-03
BR122024000903A2 (pt) 2024-02-27
CL2019001144A1 (es) 2019-07-19
EP3660040A2 (en) 2020-06-03
EP3660040A3 (en) 2020-07-29
KR102049647B1 (ko) 2019-11-29
CR20170208A (es) 2017-07-17
US20190092833A1 (en) 2019-03-28
TN2017000178A1 (en) 2018-10-19
KR20190069622A (ko) 2019-06-19
PE20170957A1 (es) 2017-07-13
SV2017005445A (es) 2018-04-04
US20170355743A1 (en) 2017-12-14
BR112017010481A8 (pt) 2023-04-11
AU2018211207B2 (en) 2020-04-09
CN108064173B (zh) 2021-05-18
JP2019011357A (ja) 2019-01-24
GT201700104A (es) 2018-11-27
IL252257A0 (en) 2017-07-31
BR122024000898A2 (pt) 2024-02-27
CN112494656A (zh) 2021-03-16
JP2018501203A (ja) 2018-01-18
CA3014641A1 (en) 2016-05-26
AR102712A1 (es) 2017-03-22
JP6703068B2 (ja) 2020-06-03
JP6484337B2 (ja) 2019-03-13
KR102101136B1 (ko) 2020-04-14
EP3666792A3 (en) 2020-07-29
ES2946247T3 (es) 2023-07-14
JP6943825B2 (ja) 2021-10-06
SG10201809457YA (en) 2018-11-29
US20170107268A1 (en) 2017-04-20
TW201625673A (zh) 2016-07-16
CA2966765A1 (en) 2016-05-26
EP3666792B1 (en) 2024-12-18
US10017556B2 (en) 2018-07-10
AU2015349890B2 (en) 2018-08-30
EP3660040B1 (en) 2025-06-18
SG11201704064TA (en) 2017-06-29
JP2019014734A (ja) 2019-01-31
CO2017004976A2 (es) 2017-10-10
SG10201809427SA (en) 2018-11-29
EA036714B1 (ru) 2020-12-10
CL2017001288A1 (es) 2017-12-15
EP3666792A2 (en) 2020-06-17
US10800827B2 (en) 2020-10-13
MX2020014120A (es) 2021-03-25
DOP2017000124A (es) 2017-08-15
CN108064173A (zh) 2018-05-22
SG10201809428UA (en) 2018-11-29
ZA201703238B (en) 2018-05-30
EP3221343B1 (en) 2020-09-16
KR20170084300A (ko) 2017-07-19
MX2017006651A (es) 2017-08-21

Similar Documents

Publication Publication Date Title
NI201700060A (es) Agonistas parciales del receptor de insulina
UY36179A (es) Derivados de exendina-4 como agonistas selectivos del receptor de glucagón
BR112017012364A2 (pt) pré-tratamento rápido.
IN2015DE00625A (es)
ES2914082T8 (es) Procedimiento de generación de progenitores de células T
FR3023171B1 (fr) Autoinjecteur.
FR3023170B1 (fr) Autoinjecteur.
ECSP17039183A (es) Agonistas parciales del receptor de insulina
EA201991576A1 (ru) Частичные агонисты инсулинового рецептора
GT201700043S (es) Pico para lavaplatos
TN2014000468A1 (fr) اختراع الة للف شباك مراكب الصيد البحري و تسهيل تحويلها من المركب الى رصيف الميناء ثم ارجاعها للمركب بعد القيام بعملية ترقيعها
TN2014000355A1 (fr) طريقة مبتكرة لتوفير الاضاءة العامة و المنزلية
ES1119305Y (es) Lámpara de mesa
TN2014000377A1 (fr) طائرة كهربائية كاتمة للصوت
GT201400039S (es) Diseño de bici-motocicleta
ITCE20140004U1 (it) Salvabimbi del dr. cirillo
TN2014000384A1 (fr) نظام صوتي ذكي وآمن
CR20140455S (es) Grua de portico
ES1106783Y (es) Mesa de cultivo
CL2014003446S1 (es) Mesa.
CR20140458S (es) Grúa de pórtico
TN2014000388A1 (fr) منظومة فيزيائية متجانسة كهربائية ميكانيكية مغناطيسية لتوليد الطاقة الكهربائية الحرة الايكولوجية المضاعفة
TN2014000354A1 (fr) جهاز مبتكر لتلقيح النخيل
GT201400051S (es) Escúter o motoneta
TH1501006949A (th) องค์ประกอบที่มีเอทิลีนเป็นองค์ประกอบหลัก